Skip to Content

Veverimer FDA Approval Status

FDA Approved: No
Generic name: veverimer
Company: Tricida, Inc.
Treatment for: Metabolic Acidosis

Veverimer (TRC101) is a non-absorbed, orally-administered polymer in development for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD).

Development Timeline for veverimer

DateArticle
Aug 24, 2020Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD
Nov 14, 2019Tricida Announces FDA Acceptance of New Drug Application for Veverimer
Sep  4, 2019Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease
Jun 25, 2019Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.